Cadila Healthcare gets EIR for Baddi plant from USFDA Kumar Jeetendra | May 29, 2020 An Establishment Inspection Report (EIR) from U.S. Food and Drug Administration (USFDA) has been gotten by Cadila Healthcare’s assembling office at Baddi, India, arranging the office as ‘No Action Indicated (NAI)’. An examination by USFDA had been directed at the office from March 02 to March 09, 2020, which finished with nil perceptions. USFDA had …
